Organic Active Ingredients TRIZ Cases

Fc-containing formats pair anti-HLA-A2/NY-ESO binding with longer circulation, addressing the short half-life of Fc-free bispecific antibodies.

Using 212Pb with a PSMA-targeting ligand, this case addresses salivary-gland uptake and xerostomia while treating prostate cancer.

A 9-nucleoside modified oligonucleotide targets upregulated miR-17 family members to slow PKD cyst growth and improve kidney function.

Conventional glioblastoma treatments have not improved survival; subtype-targeted miRNA combinations inhibit tumor growth and aggressiveness.

Selective 17βHSD13 inhibition targets a liver-disease pathway directly, rather than only managing obesity, diabetes, or dyslipidemia.

Current Aβ-focused therapies show limited effect; grapevine stem extract targets HSV-1, amyloid beta, and tau phosphorylation.

An amino acid and peptide composition helps lower liver-damage markers and reduce oxidative stress and inflammation after drug exposure.

Low-dose mifepristone blocks glucocorticoid receptors to improve insulin sensitivity while limiting cortisol elevation and HPA-axis activation.

A PNP hydrogel accommodates immunomodulatory cargos of different sizes and chemical natures for coordinated local release.

Covalent orthosteric compounds target HER2 exon 20 mutant kinases while sparing EGFR wild type to address dose-limiting toxicity.

Changing cholesterol oxidation sites tunes nanoparticle tropism, directing therapeutic RNA toward liver non-hepatocytes such as Kupffer and endothelial cells.

Existing MNK inhibitors enable target verification but lack clinical application; this case develops polycyclic compounds for MNK1/MNK2 inhibition.

Penetration enhancers such as DMSO and diethyleneglycol monoethyl ether help endoxifen cross skin while limiting systemic exposure.

Substituted thienopyrrole compounds target TLR7 and TLR8 while addressing potency and pharmacokinetic stability in lupus therapy.

Novel Compound 1 salts and crystalline forms improve solubility and bioavailability, supporting lower doses and fewer side effects.

Minoxidil and finasteride can cause side effects and slow results; pulchinenoside B4 or B5 supports rapid hair growth without toxic effects.

Exercise and nutritional supplements have limited efficacy for liver-disease sarcopenia; rifaximin adds a pharmacological option linked to muscle gains.

See how cyclodextrin complexation improves furosemide solubility and stability at physiological pH for subcutaneous or intravenous delivery.

Targeted RNA agents inhibit myeloid activation factors to reduce retinal neovascularization in AMD, ROP, and diabetic retinopathy.

Dry powder inhalation uses diketopiperazine particles to deliver a kinase inhibitor to lung tissue while reducing gastrointestinal and hepatobiliary side effects.

Chemical derivatives target MRGX2 to limit mast cell degranulation and inflammation in atopic dermatitis, chronic urticaria, and asthma.

Trimeprazine offers a treatment approach for chronic trigeminal neuralgia when conventional pain relief loses effectiveness over time.

Novel STK17A inhibitor compounds are developed for SF3B1-mutated malignancies, leukemia, and myelodysplastic syndromes.

Tau-selective compounds avoid photoisomerization while supporting accurate detection of deposits in in vitro and in vivo applications.

Conventional therapies can leave resistant cancer stem cells behind; selective CDK4/6 inhibition targets CSC proliferation to limit recurrence and metastasis.

Selective PARP1 compounds spare PARP2 to address blood and gastrointestinal side effects while supporting blood-brain barrier penetration.

Protein-bound tryptophan particles use α-lactalbumin interactions to improve stability and bioavailability while reducing bitterness in food products.

A breakable seal separates the lyophilized product from its reconstituting solution until mixing, reducing handling and exposure risks.

RAC1 inhibitors provide an alternative molecular pathway for bronchodilation when severe asthma needs more than conventional corticosteroids and beta-2 agonists.

Quinoline-substituted isoindolinone compounds bind CRBN and induce Ikaros/Aiolos and GSPT1 degradation for therapeutic use.

Volatile silicone fluid helps drug nanoparticles cross the stratum corneum while limiting irritation and systemic absorption.

Traditional copper chelators can lack metal specificity and cause toxicity; this case uses tetradentate ligands to selectively deplete copper in cancer cells.

An electrophilic pyrimidine compound enables covalent FGFR1 kinase binding to address mutant resistance and inhibit lung cancer cell proliferation.

USP14-binding chimeras recruit CERT to the 26S proteasome without E3 ligases, depleting the target and sensitizing cancer cells to HER2 therapy.

An immediate-release ivermectin–albendazole combination enables water-free dosing and helps limit resistance risk in helminth treatment.

Measure Clostridium hiranonis and related gut microbes against reference abundances to identify dogs responsive to hydrolyzed protein diets for chronic enteropathy.

Existing routes struggle to produce suitable crystalline drug forms; controlled solvents, temperature, and pH enable pharmaceutical-grade compounds.

Specific substituents and heteroatoms tune the fused bicyclic structure toward PARP1 selectivity, reduced toxicity, and chemotherapy compatibility.

Existing HBV drugs can suppress viral DNA without clearing HBsAg; this compound adds immune activation to pursue functional cure.

Pulmonary microparticles help deliver triptans rapidly while limiting peripheral and vascular degradation in migraine treatment.

See how fed-state dosing with naltrexone and bupropion addresses food-effect gaps, raising Cmax by 91–271% and AUC by 70–107%.

Controlled cooling and anti-solvent addition produce TETA.4HCl Form B with improved room-temperature stability and less humidity sensitivity.

Limited antiviral efficacy is addressed with 2′,3′-dihydroxy-4′-fluoromethyl nucleosides for Flaviviridae and Pneumoviridae infections.

An enteric coating holds the PRS inhibitor in acidic gastric conditions and releases it in the intestine to reduce nausea and vomiting.

Nuclease degradation and poor cellular uptake limit nucleic acid medicines; multibranched lipids protect and deliver them for gene silencing.

Lipo-hydroxamic acid derivatives convert into lipoic acid for topical use, improving corneal absorption while limiting mucosal irritation.

Chemical modification of saponins supports endosomal toxin release while reducing cytotoxicity and hemolytic activity for a wider therapeutic window.

Warm-microbiota strains such as Parabacteroides modulate gut bacteria and increase bone density in osteoporosis treatment.

Late acetaminophen injury can outlast N-acetyl cysteine’s treatment window; pre-polarized macrophages reduce necrosis and support liver regeneration.

Blocking CYP26 raises atRA levels, enhancing mitochondrial biogenesis and neuronal growth in SURF1-dependent Leigh syndrome.